Lead Product(s): Danicopan
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: $930.0 million Upfront Cash: $930.0 million
Deal Type: Acquisition January 28, 2020
Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases.